Modified factor VII
AssigneesZymoGenetics, Inc., Novo Nordisk A/S
InventorsCharles E. Hart, Lars C. Petersen, Ulla Hedner, Mirella E. Rasmussen
Life of this patent
Estimating the term…
Abstract
The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The invention relates to novel methods of treatment and uses of modified Factor VII for preventing or treating myocardial injury associated with post-ischemic reperfusion, for improving regional myocardial blood flow during reperfusion, and maintaining or improving vascular patency in a patient, as well as topical application of modified Factor VII at vascular sites susceptible to thrombus formation.
Claims8
A method for inhibiting thrombus formation in a patient comprising administering topically to a vascular site susceptible to thrombus formation in the patient a therapeutically effective dose of a composition comprising human Factor VIIa having at least one covalent modification in its catalytic center, which modification substantially inhibits the ability of the modified human Factor VIIa to activate plasma Factor X or IX.
A method for maintaining or improving vascular patency in a patient comprising administering locally to a vascular site susceptible to decreased patency a therapeutically effective dose of a composition comprising human Factor VIIa having at least one covalent modification in its catalytic center, which modification substantially inhibits the ability of the modified human Factor VIIa to activate plasma Factor X or IX.
Dependencies are inferred from the claim text.